Capricor Therapeutics (CAPR) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Capricor Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update
November 10, 2016 4:07 PM ESTLOS ANGELES, Nov. 10, 2016 /PRNewswire/ --Â Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and other serious medical conditions, today provided a corporate update and announced financial results for the third quarter ended September 30, 2016.
Linda Marbán, Ph.D., president and chief executive officer, said, "The third quarter was marked by meaningful progress in the development of our lead candidate, CAP-1002 (allogeneic cardiosphere-derived cells), as we completed treatment in both... More
